SCHEMBL830616

SCHEMBL830616

O=c1[nH]c2cc(Br)cc(Br)c2cc1S(=O)(=O)/C=C\c1ccc(Cl)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.37
MEN1 O00255 4/20 0.37
POLB P06746 3/20 0.37
TNF P01375 1/20 0.35
NOD1 Q9Y239 1/20 0.35
PARP1 P09874 1/20 0.34
MAPT P10636 6/20 0.33
ALDH1A1 P00352 4/20 0.33
LMNA P02545 4/20 0.33
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
ALPL P05186 1/20 0.33
GLA P06280 1/20 0.33
ALPG P10696 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830507 1.00 KMT2A (0.37) KMT2AMEN1POLBTNFNOD1
SCHEMBL830506 1.00 KMT2A (0.37) KMT2AMEN1POLBTNFNOD1
SCHEMBL830387 0.85 DAO (0.36) PARP1MAPTKDM4ERAB9ANPC1
SCHEMBL830388 0.85 DAO (0.36) PARP1MAPTKDM4ERAB9ANPC1
SCHEMBL831069 0.85 DAO (0.36) PARP1MAPTKDM4ERAB9ANPC1
SCHEMBL830733 0.79 DAO (0.46) KMT2AMEN1POLBTNFNOD1
SCHEMBL830184 0.79 DAO (0.46) KMT2AMEN1POLBTNFNOD1
SCHEMBL830183 0.79 DAO (0.46) KMT2AMEN1POLBTNFNOD1
SCHEMBL830633 0.77 MAPT (0.46) KMT2AMEN1POLBTNFNOD1
SCHEMBL830632 0.77 MAPT (0.46) KMT2AMEN1POLBTNFNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 KMT2A 484/4885MEN1 979/4885POLB 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.